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ABSTRACT 
Primary immunodeficiencies (PID) are congenital disorders of immune competence, which are 
mainly characterized by a pathological susceptibility to infection. This is often accompanied by 
severe recurrent infections with drug-resistant, long progressions. In addition, there are associated 
immune regulation disorders, which may manifest themselves in granuloma formation, auto-
immunity, recurrent fever, eczema, lymphoproliferation and chronic intestinal inflammation. 
More than 240 disease entities have been defined so far as PID, and just as extensive is the 
spectrum of clinical severity. While the most common congenital immunodeficiencies, such as 
selective IgA deficiency or C2 complement deficiency, have a mild phenotype which often 
remains undetected, severe PID are characterized by significant mortality in the first years of life, 
as well as a serious morbidity with irreversible organ damage. This applies in particular to PID 
that are defined by the absence or functional anergy of T-lymphocytes (severe combined 
immunodeficiency; SCID) or B-lymphocytes (e.g. X-linked agammaglobulinemia; XLA). 
Patients with such severe congenital immunodeficiencies appear to be in perfect health at birth, 
yet show initial manifestations of SCID between the 14th day and the 4th month following birth; 
in patients with XLA usually between the 8th and 16th month after birth. 
Albeit increasingly becoming appreciated as a relevant health problem, there is a lack of 
diagnostic procedures and screening profiles that would allow earliest possible diagnosis of 
patients with severe PID on a population scale. As a superior prognosis could be given upon 
prompt diagnosis and immediate adequate treatment, one strategy to improve the outcome of 
severe PID shall be to test newborns for the presence of T and B cells. With the aim to develop a 
simple and reliable test for newborn screening using the established dried blood sampling system 
(Guthrie cards), a multiplex real-time quantitative qPCR assay for the quantitation of T cell 
receptor excision circles (TRECs) and kappa-deleting recombination excision circles (KRECs) as 
surrogate markers of T and B cell development was designed and evaluated (publication I). This 
assay was further extended to allow detection of newborns with an inversion of the UNC13D 
gene, causing a severe PID characterized as familial hemophagocytic lymphohistiocytosis 
(publication III). Furthermore, the feasibility to identify several other severe PID, characterized 
by a functional defect of T- and B-cell interation (combined immunodeficiency diseases), was 
assessed using IgA-protein detection in neonatal Guthrie cards. However, this assay provided 
evidence of a maternal transfer mechanism for IgA, thereby preventing the use of this assay as a 
screening tool for severe PID (publication II). Finally, the TREC-KREC newborn screening assay 
was further improved in terms of assay performance and evaluated in retrospective cohorts of 
patients with the DiGeorge syndrome, or Down syndrome (publications IV and V). In addition, 
novel second-tier assays for comfirmation of the 22q11 microdeletion or the chromosome 21 
triplication have been designed and succesfully tested with neonatal samples.    
In summary, new assays and concepts for newborn screening of severe primary 
immunodeficeincies were designed and benchmarked in retrospective and prospective neonatal 
dried blood spot samples, thereby underlining the potential of this preventive health care strategy.   
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Foreword 
 
     This thesis comprises diagnostic assays and studies applied to the 
identification of primary immunodeficiency diseases (PID) at the neonatal stage. 
While the concept of newborn screening is not new, its broader application to 
severe PID has only come into action in recent years. Originating from pilot 
studies initiated in the United States in 2008, more than 3 million newborns have 
been screened so far for severe combined immunodeficiency (SCID), resembling 
one of the diseases at the severe end of PID in terms of disease-related morbidity 
and mortality.  
My intention, when starting to conduct and organize research in the field of 
neonatal testing for PID, was to extend the concept of SCID screening to other 
relevant diseases such as inborn agammaglobulinemias, hemophagocytic 
lymphohistiocytosis, and eventually defects of phagocytic cell function. 
Furthermore, my aim was to evaluate newly developed multiplex assays in 
retrospective and prospective cohorts to support the broader implementation of 
newborn screening tests for PID. It is rewarding to see what has been achieved 
during the past few years for the sake of our patients.  
 
 
 
Leipzig, August 10, 2014 
Stephan Borte 
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INTRODUCTION 
 
1.1     Clinical concepts of immunodeficiencies 
     A compromised or abolished function to fight infectious diseases is a major 
hallmark of immune deficiencies, most commonly resulting from an acquired 
condition such as iatrogenic immunosuppression (e.g. chemotherapy, radiation, 
glucocorticoids and anti-rheumatic drugs), malnutrition, aging, malignancies or 
metabolic diseases, as well as referred by the pathomechanism of chronic 
infections. In clinical practice, the cause and effect of acquired 
immunodeficiencies often is well-documented, yet sometimes of complex 
nature. Besides, the clinical description of the functional relevance of an 
acquired immune defect is mostly driven by the choice of therapeutic options 
available, such as antimicrobial treatment in asplenia, immunoglobulin 
replacement therapy for humoral deficiencies, hematopoietic growth factor 
supplementation in neutropenia, and hematopoietic stem cell transplantation 
(HSCT) or gene therapy (GT) for hematopoietic lineage defects. 
Primary immunodeficiencies, however, are inborn defects of the immune 
response and closely relate to our understanding of basic to advanced concepts of 
immunobiology. As immunology is a relatively new science, it is intrinsically 
tied to the mechanisms of host and microbe interaction and response, described 
first in discoveries of Edward Jenner, Robert Koch, Louis Pasteur, Emil von 
Behring, Shibasaburo Kitasato and Elie Metchnikoff. This mechanistic view has 
provided the framework for researchers and doctors to classify PID according to 
the component of the immune system that predominantly is associated with the 
observed course and phenotype of infectious complications: innate versus 
  11 
adaptive immune defects; including B cell-, T cell-, and NK-cell disorders, as 
well as granulocyte defects and complement deficiencies. Furthermore, the 
networked interaction of immune cells is represented in definitions such as 
‘combined immunodeficiencies’, with two or more immune components being 
affected in function or number, or ‘disorders of DNA repair, somatic 
hypermutation and class switching’ for molecular defects that affect several cell 
types. However, definitions and diagnostic criteria for PID are fluidic and subject 
to ongoing refinement (1-3). 
 
1.2     Primary immunodeficiency diseases (PID) 
     Genetically determined disorders of protective immune function are 
commonly referred to be primary immunodeficiency diseases and have been 
recognized clinically already 60 years ago with the identification of X-linked 
agammaglobulinemia. Today, the group of PID involves over 200 distinct 
entities which are scattered to present as phagocytic disorders, complement 
deficiencies, T-cell deficiencies and - predominantly - antibody disorders (1).  
In his enigmatic case report published 1952 in Pediatrics, Ogden Carr Bruton 
depicted the clinical course, diagnostic workup and therapeutic approach of an 8-
year old boy with absent serum immunoglobulins and severe infectious 
complications, including several episodes of pneumonia, recurrent otitis media 
and osteomyelitis (4). The case procedures already anticipated the patient-
centered approach that is taken nowadays to identify primary immunodeficiency 
diseases based on warning signs circularization and clinical pattern education in 
order to alleviate or prevent the impact of a delayed diagnosis. In addition, 
sophisticated diagnostic tools such as molecular assays suitable for high-
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throughput screening of newborns have found their way to the PID field and are 
currently undergoing evaluation if this step of preventive health care balances the 
total expenditures for such screening programs compared to the efficiency to 
diagnose, treat and improve the long-term outcome of PID patients (5). Finally, a 
modern management of patients requiring substitution of immunoglobulin 
products, including those diagnosed with (severe) combined 
immunodeficiencies, primary B-cell immunodeficiencies and selected disorders 
such as the Wiskott-Aldrich syndrome, has advanced to provide a more 
sustainable therapeutic effect and to improve the patients` quality-of-life than 
merely replacing antibody protection (6,7). 
Despite these achievements in the field, patients with primary antibody 
deficiencies in particular are still prone to a significant diagnostic delay, thereby 
promoting an increased likelihood to develop and progress infection-associated 
organ damage (8,9). The chronic lung disease, characterized by moderate to 
severe bronchiectasis observed in these patients, remains an unresolved threat to 
the overall life expectancy despite virtually normal levels of serum 
immunoglobulin G (IgG) following replacement therapy (10,11). The clinical 
experience gathered throughout the years endorses disease awareness and should 
guide research into newborn screening, disease progression and future 
therapeutic strategies (12). 
Primary immunodeficiencies are not rare diseases and should be considered in 
all patients with severe or recurrent infections admitted to health care centers. 
The summarized prevalence ranges from 1 in 500 to 1 in 2.000 of the general 
population, yet PID are misdiagnosed in many cases because of their prolonged 
course of disease which often worsens the outcome (8). However, the estimated 
incidence of severe PID, which is those that would require immediate treatment, 
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ranges from 2 - 8 per 100.000 live births, making high demands on the 
effectiveness and availability of diagnostic tests to detect them as soon as 
possible. The European Society for Immunodeficiencies (ESID) has enrolled 
more than 15.000 PID patients into a database, allowing deciphering the 
diagnostic delay and factors influencing prognosis and quality-of-life (13). The 
registry data indicates that PID associated with acute serious infections, such as 
severe combined immunodeficiencies (SCID), had the shortest median delays 
until diagnosis (0.1 – 0.2 years). In contrast, patients with antibody deficiencies 
were prone to a very long diagnostic delay (4 - 10 years), presumably as a result 
of the less-life-threatening infections dominating the clinical presentation, paired 
with a lack of awareness towards PID among the medical professionals (8). In 
order to reduce the significant morbidity related to antibody deficiency diseases 
and to improve patients` quality-of-live and the overall survival, critical 
importance has to be attached to strategies that would allow earliest-possible 
diagnosis of these patients, e.g. by means of newborn screening, and prompt 
initiation of immunoglobulin replacement therapy as well as further supportive 
care. 
 
1.3     Neonatal testing and newborn screening 
     The purpose of neonatal testing is the early recognition of treatable, mostly 
genetically-determined diseases that manifest with a high rate of morbidity and 
mortality. Mass screening of newborn infants started in the early 1960s based on 
a method developed by Robert Guthrie and Ada Susie for the screening of 
phenylketonuria (14,15). Peripheral blood from a heel stick was blotted on filter 
paper (later on often referred as ‘Guthrie card’) at two to five days after birth, 
dried and sent by postal mail to centralized laboratories for analysis. Once this 
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sampling procedure was established, new disorders were considered for NBS 
and it became necessary to create procedures for decision-making, to help 
deciding which diseases were suitable for a population-based screening. A 
conference arranged by the World Health Organization (WHO), originally 
intended to discuss screening for cancer in adults, resulted in a paper written by 
James Wilson and Gunnar Jungner describing ten criteria, to be considered when 
a new disorder is proposed for mass screening (16). 
The addition of new diseases in neonatal screening programs has been critically 
determined by the development of methods suitable for the analysis of large 
numbers of samples up until the mid-1990s. The technological progress since 
then, allowing simultaneous determination (‘multiplexing’) of several hundreds 
of metabolites in dried blood spot samples (DBS) from filter paper, together with 
novel techniques for the analysis of nucleic acids (DNA and RNA), 
revolutionized newborn screening. However, with these breakthrough 
technologies being broadly available, the choice of disorders to be included in 
NBS has to be carefully scrutinized with respect to cost benefit considerations, 
the patient perspectives and social acceptance. The complex of problems 
associated with this process is illustrated by differing decisions made in different 
countries (14). 
In the USA, the congress decided in 2003 to include 29 core and 25 secondary 
disorders in the NBS program, adding up to a total of 54 inborn diseases that are 
screened for in newborns. This decision was motivated by thorough 
investigations, resulting in a priority list of disorders suitable for neonatal 
screening (17). In recent years, more disorders have been included in this list of 
recommended diseases to be screened all over the US – one of them being SCID 
(18). At the other extreme, a health technology assessment (HTA) performed in 
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Great Britain in 2004 came to the conclusion that a substantial benefit by 
neonatal screening, based on a multiplexing technology, could only be shown for 
two disorders (19). Thus, only five disorders are currently included in the general 
newborn screening program in Great Britain. A recent investigation of the 
various approaches towards NBS evaluation in different European countries 
illustrates the considerable heterogeneity of the included disorders, as well as the 
diversity of the organizational structure of the NBS programs (20). 
Newborn screening for SCID as a representative of a severe PID has already 
been proposed in the late 1990s by Jennifer Puck and Rebecca Buckley, 
suggesting that a complete (differential) blood count (CBC) might help disclose 
SCID newborns based on a reduced absolute lymphocyte count (ALC) per 
milliliter of blood. As this method would have to rely on fresh blood samples 
from every newborn tested, the efforts for sample logistics and handling would 
prevent a large-scale implementation. In addition, T-B+NK+ SCID genotypes 
with elevated numbers of B- or NK-cells might return false-negative test results. 
Later on, ELISA-like immunoassays for Interleukin-7 were proposed for SCID 
screening, yet technical issues of inferior sample stability and tedious protein 
purification prevented broader evaluation (21). Similarly, bead-capture assays 
for the T-cell receptor-CD3 complex and CD45 were developed, but false-
negative results in SCID patients with maternal engraftment or expansion of 
oligoclonal T cells have been reported, thereby disqualifying this technique from 
implementation (22). As the availability of a suitable test or examination, that is 
acceptable to the general population, is a critical prerequisite for evaluation of 
proposed diseases to be included in NBS programs, it took until 2009 when Mei 
Baker and Jack Routes returned solid proof for the suitability of the T-cell 
receptor excision circle (TREC) assay for SCID screening (23). 
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1.4     Guidelines for newborn screening of severe PID 
     Severe PID represent a small fraction of all primary immunodeficiency 
diseases grouped by the clinical need for early and curative or lifelong 
therapeutic intervention to prevent progressive morbidity or, ultimately, early 
mortality. Thus, from a clinical point of view, one can imagine a number of 
severe PID to be evaluated for the development of screening tests and for 
subsequent inclusion in newborn screening programs. These include, but are not 
limited to: 
 Deficiency of absolute numbers of T cells; i.e. in SCID or complete 
DiGeorge syndrome 
 Defects of the function of T and B cells; i.e. in profound combined 
immunodeficiencies such as MHC defects and IKK2 deficiency 
 Deficiency of absolute numbers of B cells; i.e. in XLA 
 Deficiency of absolute numbers of phagocytes; i.e. in Kostmann 
syndrome 
 Defects of neutrophil function; i.e. in chronic granulomatous disease 
 Deficiency of NK cell function; i.e. in FHL 
 Congenital thrombocytopenias; i.e. in Wiskott-Aldrich syndrome 
 
Even given that different concepts for NBS evaluation exist, most countries 
warrant compliance of the proposed diseases with the original Wilson-Jungner 
criteria for mass screening (14), consisting of the following ten items: 
1. The condition sought should be an important health problem. 
2. There should be an accepted treatment for patients with recognized 
disease. 
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3. Facilities for diagnosis and treatment should be available. 
4. There should be a recognizable latent or early symptomatic stage. 
5. There should be a suitable test or examination. 
6. The test should be acceptable to the population. 
7. The natural history of the condition, including development from 
latent to declared disease, should be adequately understood. 
8. There should be an agreed policy on whom to treat.  
9. The cost of case finding (including diagnosis) should be 
economically balanced in relation to possible expenditure on 
medical healthcare as a whole. 
10. Case finding should be a continuing process and not a “once and 
for all” project. 
 
As the framework of the Wilson-Jungner criteria was not strictly designed to fit 
the demands of a neonatal screening evaluation, several countries have made 
more specific amendments (14,20). Moreover, to improve the ability of decision 
makers and public health practitioners to stratify disease-specific aspects in the 
context of a newborn screening setting, it was suggested to expand the Wilson -
Jungner framework by supplemental items (24,25):  
11. There should be scientific evidence of screening program 
effectiveness and the benefits of screening should be shown to 
outweigh the harm. 
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12. The test may be multiplexed or overlaid onto an existing structure 
or system. 
13. The “diagnostic odyssey” for the patient/family may be reduced or 
eliminated. 
14. Adverse outcome(s) are rare with a false-positive test. 
15. Treatment costs may be covered by third parties (either private or 
public). 
16. Testing may be declined by parents/guardians. 
17. Adequate pretesting information or counselling is available to 
parents/guardians. 
18. Screening in the newborn period is critical for prompt diagnosis 
and treatment. 
19. Public health infrastructure is in place to support all phases of the 
testing, diagnosis, and interventions. 
20. If carriers are identified, genetic counselling is provided. 
21. Treatment risks and the impact of a false-positive test are 
explained to parents/guardians. 
22. The limitations of screening and risks of a false-negative test are 
explained to parents/guardians. 
 
To demonstrate the practical guidance that is given by the extended Wilson-
Jungner framework, a brief evaluation of two severe PIDs currently not included 
in routine newborn screening programs is shown in Table 1.  
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Table 1. Application of the 22-item extended framework of Wilson-Jungner 
criteria to advocate agammaglobulinemias (e.g. XLA) and inherited 
hemophagocytic syndromes (e.g. FHL3) to be considered for implementation in 
newborn screening programs (14). 
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AIMS 
 
2.1     General research aim 
     The general aim of the work presented in this thesis was to develop and 
evaluate novel diagnostic assays to be used for newborn screening of severe 
primary immunodeficiencies, including SCID, XLA and FHL3 due to an 
UNC13D inversion.  
 
2.2     Specific scientific aims 
      
     Publication 1: To design, develop and benchmark a triplex high-throughput 
real-time quantitative PCR assay for simultaneous detection of TREC, KREC 
and ACTB copy numbers in single neonatal dried blood spot punches. 
 
     Publication 2: To evaluate the feasibility and usefulness of an IgA-protein 
screening assay for identification of primary immunodeficiency diseases in 
newborns. 
      
     Publication 3: The development and evaluation of a combined newborn 
screening test for familial hemophagocytic lymphohistiocytosis due to an 
UNC13D inversion, as well as severe T and B cell immunodeficiencies. 
      
     Publication 4: To improve the performance of the TREC-KREC-ACTB 
screening assay from Publication 1, to study its performance in neonatal samples 
from Down syndrome patients, and to develop a second-tier test for Trisomy 21. 
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     Publication 5: The assessment of the performance of the TREC-KREC-
ACTB screening assay in predicting the clinical phenotype of infants with 
DiGeorge syndrome and to engineer a second-tier test for the 22q11 
microdeletion. 
 
2.3     Translational aim 
     The translational aim of this thesis was to promote the concept of newborn 
screening for several severe PID in one assay, and to motivate local prospective 
screening studies to be conducted. 
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HUMAN SUBJECTS, MATERIALS AND METHODS 
 
3.1     Study populations and biobanked patient samples 
     The included PID patients and their stored neonatal Guthrie card samples 
have accumulated over many years. Most patients were treated or followed at the 
immunodeficiency or hematology hospital wards in Huddinge, Gothenburg or 
Lund (all Sweden), or in Leipzig and Freiburg (both Germany). All patients or 
their parents gave informed consent to obtain, use and store DBS and other 
available biological material. Ethical votes were obtained at Karolinska 
Institutet, Stockholm, Sweden, and the Medical Chamber of Saxony, Dresden, 
Germany. Guthrie card samples from the included patients, as well as storage-
time matched anonymized control cards were obtained from storage at room 
temperature or at +4°C, and were subsequently biobanked in individually sealed 
bags containing a silica humidifier at -80°C for long-term storage. 
For prospective screening studies, a fraction of the regular neonatal screening 
card (Whatman 903 or PerkinElmer 206 paper) was allocated for the TREC-
KREC-ACTB or TREC-KREC-UNC13Dwt assay at the Centrum för Medfödda 
Metabola Sjukdomar (CMMS) in Stockholm. In Leipzig, a separate screening 
card (Whatman 903 paper) was provided to the participating maternity clinics. 
Further information about the included study populations and dried blood spot 
specimen is included in the methods sections of publications I-V. 
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3.2     Extraction of DNA from dried blood spots 
     During initial investigations and for verification of disease-causing mutations 
in DBS, several 3.2mm disk punches were processed using the Qiagen QIAamp 
DNA Mini Kit according to the manufacturer’s instructions. For newborn 
screening purposes, a protocol published by Mei Baker was applied (23), as 
indicated in publications I, III, IV and V. This protocol consists of the assay 
reagents included in the Qiagen Generation Capture Kits, and releases DNA 
from the DBS by heat-incubation at 99°C in a 96-well PCR plate. For the newly 
developed SCREEN-ID kit-like assay, a proprietary rinse solution was 
developed at TRM Leipzig, which is similar in terms of chemical composition 
with the above mentioned commercially available reagents. 
 
3.3     Elution of proteins from dried blood spots 
     Protein-containing eluates from DBS were prepared as described in 
publication II. In detail, single 3.2mm disk punches from stored Guthrie cards 
were distributed into single wells of deepwell-plates and incubated in 450 μl of 
phosphate-buffered saline (PBS) with 0.5% Tween20 under varying conditions 
for temperature (4°C – 37°C) and elution time (1 h – 7 days). To determine the 
most efficient elution procedure for IgA from DBS, serum IgA levels of freshly 
collected blood specimens were compared with the IgA levels of eluates from 
dried blood filter cards, prepared using the same blood samples. The serum 
levels of IgA were determined by routine nephelometry, while the IgA levels in 
the DBS eluates were determined by ELISA.  
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3.4     Preparation of plasmid standards for PCR-based quantitation 
     A ‘TREC-KREC-TRAC’ plasmid (pCR2.1-TOPO, TREC signal joint insert: 
380 bp, TRAC insert: 367 bp, KREC signal joint insert: 168 bp) was kindly 
provided by Alessandra Sottini and Luisa Imberti, and a ‘beta-actin’ (ACTB) 
plasmid (pCR2.1-TOPO, human beta-actin DNA insert: 348 bp) was obtained 
from the lab of William J. Grossmann and Donna K. Mahnke. The UNC13Dwt 
plasmid was generated from amplified human whole blood DNA, sub-cloned 
into the pCR 2.1-TOPO vector (Life Technologies), using primers detailed in 
publication III. 
Following transformation and cloning of each plasmid in competent E. coli cells, 
the bacteria were harvested from culture and plasmid DNA was isolated using 
the Qiagen Plasmid Midi Purification kit according to the manufacturer`s 
instructions. Subsequently, the plasmid DNA was digested using Xho I 
restriction enzyme, and extracted on a 1% agarose gel (130V, 40 minutes) before 
purified using a Qiagen Gel Extraction Kit. Plasmid stock solutions were 
prepared according to the calculated molecular weight of each plasmid, and 
stored in H20 supplemented with yeast tRNA (Ambion) at -25°C.  
 
3.5     Real-time multiplex quantitative PCR reactions 
     During normal development of B and T cells, their immune receptors will 
undergo rearrangement processes to shape their specificity, resulting in genomic 
excision products. The rearrangement of the T-cell receptor (TCR) gene 
segments, that enables the diversity of the TCR, gives rise to T-cell receptor 
excision circles (TRECs) and the rearrangement of the kappa light-chain locus 
that contributes to antibody diversity of B cells will lead to the formation of 
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kappa-deleting recombination excision circles (KRECs). For amplification of the 
signal-joints of TRECs and KRECs, primers and hydrolysis (TaqMan) probes 
published by Alessandra Sottini were used (30), and for amplification of ACTB, 
primers and hydrolysis (TaqMan) probes published by Daniel Douek were used 
(31). The primer and hydrolysis (TaqMan) probes used in publications III for 
UNC13Dwt, in publication IV for the PTBP1 gene and the KCNE1 gene, and in 
publication V for TBX1 gene quantitation were designed in-house as detailed in 
the respective publications.    
As for publication I, we have been using a commercially available qPCR master 
mix from LifeTechnologies and the real-time qPCR was performed on ABI 7500 
or ViiA7 instruments. With regard to publications III, IV and V, we have been 
placing a research and development service order at Affymetrix Incorporated for 
the allocation of a custom master mix for multiplex qPCR with inhibitor-rich 
DNA templates as typically obtained from DBS. This master mix contains a 
random-mutation-derived hot-start Taq DNA polymerase with similar properties 
as the Hemo KlenTaq polymerase, as well as nucleotides with an optimized 
dUTP:dTTP ratio, Uracil-DNA Glycosylase and  ROX passive reference dye in 
a proprietary reaction buffer.     
 
3.6     Newborn screening assays and kit versions 
     The TREC-KREC-ACTB newborn screening assay described in publication I 
is referred to be ‘version 1.0’, prior to a series of modifications aiming to (i) 
improve the assay resolution in the low-copy range of TREC and KREC 
absolute quantitation in DBS, as well as (ii) to ease the overall handling of the 
screening assay and to reduce the hands-on-time. As depicted in section 3.5, a 
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custom master mix containing an optimized Taq DNA polymerase, as well as 
improved concentrations of TREC, KREC and ACTB primers and hydrolysis 
(TaqMan) probes determined by primer-limiting assays, has been developed. 
These new core reagents allowed reducing the fraction of technically-determined 
cutoff values for TREC and KREC copies due to better low-copy range 
resolution in between patient samples and healthy newborns (Figure 1).  
 
 
Figure 1. Improvement of the low-copy range resolution of the TREC-KREC-
ACTB assay in comparison of copy numbers obtained from SCID patients 
(IL2RG gene or RAG1 gene mutations) and XLA patients (BTK gene mutations) 
either in the ‘version 1.0’ assay used in publication I (higher TREC and KREC 
values, respectively) or the ‘version 2.0’ assay used in publications III, IV and V 
(lower TREC and KREC values, respectively). Patient samples in filled circles, 
healthy newborns in open circles. 
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During the process of evaluating the TREC-KREC-ACTB screening assay in 
local prospective screening studies, it became apparent that the liquid-handling, 
the overall processing time and the related working steps require optimization to 
further improve the applicability for mass screening of this assay. Thus, we have 
been designing a hitherto unpublished kit-like ‘version 3.0’ assay that reduces 
the required liquid-handling to a single working step in replacement for short 
centrifugation steps, and have combined all required reagents and plastic ware in 
a storable format (Figure 2). The assay is available on the basis of a material-
transfer-agreement from the TRM Leipzig. 
 
3.7     Mutation-verification by Sanger sequencing 
     All PID patients included in papers I, II and III were confirmed by Sanger 
sequencing for the presence of known disease-causing mutations. Eluted 
genomic DNA from the dried blood spot punches was used to amplify the coding 
regions of the intended PID genes, with primers obtained from the RAPID 
database (32). Subsequent to gel electrophoresis, PCR products were purified 
using MSB Spin PCRapace columns from Stratec, and were sent for direct 
sequencing to the IZKF core unit at the University of Leipzig. 
 
3.8     Digital PCR product analysis 
     Following PCR with sequence specific primers and gel electrophoresis, PCR 
products were purified as indicated above. Subsequently, to investigate integrity 
and size of the PCR amplicons, separated PCR products were analyzed using 
DNA microfluidic-chips on a 2100 Bioanalyzer (both Agilent Technologies). 
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Figure 2. SCREEN-ID kit-like assay version for quantitative analysis of (i) 
TREC-KREC-ACTB or (ii) TREC-KREC-UNC13Dwt copies in neonatal DBS. 
The kit consists of pre-arranged 96-well plates containing a DNA-elution 
solution in the ‘Elution plate’, and qPCR reagents and plasmid standards for 
real-time qPCR in the ‘qPCR plate’; both plates can be stored frozen at -25°C for 
up to 6 months. Only a single pipetting step is required to wet DBS with a rinse 
solution in the ‘Filter unit’. All further assay steps rely on centrifugation of the 
plates containing DBS and assay reagents. Control card specimen are allocated 
to mimic T-cell deficient (TCD), B-cell deficient (BCD) or T- and B-cell 
deficient (TBCD) patient samples.    
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3.9     Statistical analyses 
     Comparison in between groups and correlation analysis was performed using 
XLSTAT 2013 (Addinsoft). Fisher´s exact test was used to identify differences 
between groups concerning categorical data and the Mann-Whitney U tests were 
used for continuous data. Statistical significance was defined as a p-value < 0.05. 
ROC (receiver operating characteristic) curve analyses were performed using 
standard settings in MedCalc version 14 (MedCalc Software). 
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RESULTS AND DISCUSSION 
 
4.1     Rationale for newborn screening of severe PID 
     The earliest possible diagnosis of severe PID improves their prognosis and 
treatment efficiency significantly (33-35). This stems primarily from the 
possibility to initiate early preventive measures to avoid infection, and to prevent 
iatrogenic damage, e.g. caused by the administration of recommended 
vaccinations, such as the rotavirus vaccine (live vaccine), which is safe for 
immunocompetent infants (36,37). The prevention of such complications 
significantly improves overall survival before and after performing curative 
hematopoietic stem cell transplantation (HSCT), gene therapy (GT) or 
supportive enzyme replacement therapy or immunoglobulin replacement therapy 
(33). Given the special importance of an early pre-symptomatic diagnosis of 
patients with severe PID, the implementation of newborn screenings seems 
useful (14).  
 
4.2     DNA-based newborn screening assays for severe PID 
     When applying established criteria in decision-making processes in newborn 
screening, one has to distinguish in between the target disease to be excluded and 
the applicable screening-biomarker itself. While in a number of metabolic 
diseases the respective screening marker is directly attributable to the 
pathogenesis of a target disease (e.g. in biotinidase deficiency or classic 
galactosemia), the requirements for screening markers for severe PID are more 
demanding. As SCID and XLA are pathogenetically and immunophenotypically 
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characterized by the absence of T- and/or B-lymphocytes, the target disease for 
newborn screening of these severe PID should be defined as ‘pronounced 
neonatal deficiency of autologous T- and/or B-lymphocytes’. In the evaluation of 
different laboratory methods for the detection of these PID, the measurement of 
episomal excision products of lymphocyte receptors (TRECs and KRECs) has 
prevailed, as this method, both in terms of test quality and practical feasibility, is 
consistent with prospective screenings (38). When applying the evaluation 
criteria of population-based screening tests to the measurement of TRECs and 
KRECs for the detection of the pronounced neonatal deficiency of autologous T- 
and/or B-lymphocytes, the implementation as newborn screening has been 
viewed positively (14). In several U.S. states, population-based screening 
programs for pronounced neonatal deficiency of autologous T-lymphocytes in 
newborns were initiated successfully in 2008, and now some countries in the 
European Union have begun their own pilot projects (Germany, Sweden, France, 
UK and Italy) (39,40).  
The principle of measuring episomal excision products of lymphocyte receptors 
is based on the naturally occurring recombination and affinity maturation of the 
T-cell and B-cell receptors (41). Parts are excised from the germline DNA of the 
immunoglobulin genes that are not involved in the recombination process of the 
antigen receptors. While T-lymphocytes in the thymus initially excise portions of 
the δ-locus in order to then recombine the α-locus, so-called TRECs are created, 
which spontaneously form circular DNA fragments that are not replicated further 
during cell division. Following a similar principle, a deletion occurs in B-
lymphocytes in the bone marrow during the Vk-Jk rearrangement, in the process 
of which KRECs are formed. Since these molecular processes are inter-
individually uniform, a uniform PCR strategy can be applied to determine the 
presence and number of copies of TRECs and KRECs in dried blood samples 
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from neonates (publication I). During the formation of circular DNA fragments, 
a unique sequence region (so-called signal joint) is created, which means a 
quantitative PCR method can be used to detect only the TREC and KREC 
fragments already excised from the germline DNA, so that a direct conclusion 
about the maturation of T- and B-lymphocytes that has taken place is possible. 
Given that with this method no individual sequence information is collected, the 
PCR method is most appropriately comparable to virological pathogen-load 
diagnostics. Like the established analytics of regular newborn screening, such a 
PCR method, however, becomes subject to the scope of genetic diagnostics acts. 
In other words, patients must be informed in writing by medical staff with 
proven qualifications in the field of genetic counseling. 
For the measurement of TRECs and KRECs in newborns, the use of 3.2 mm or 
1.5 mm punches from regular dried blood spot cards (e.g. Whatman 903 paper) 
has proven most useful. These can be obtained in the time frame of the 
established logistics of newborn screening (Figure 3). At the screening lab, 
TRECs and KRECs are then detected in the sample material. Either relative 
endpoint-PCR or absolute quantitative real-time PCR methods can be used. The 
use of detection probes allows for an increase in the specificity of the amplicons 
to be detected and the simultaneous measurement of several different amplicons 
(multiplexing), which further improves cost-efficacy (Figure 3). In the analytical 
chemistry to be used, one can choose from hydrolysis probes in the 5' nuclease 
assay (e.g. TaqMan; from LifeTechnologies), time-resolved fluorescence 
resonance energy transfer (TR-FRET, e.g. from PerkinElmer) and iso-dG/iso-
dC-labeled oligonucleotides with fluorescent dyes and quenchers (e.g. Plexor; 
from Promega). As experience from publications I, III, IV and V has shown, a 
two-step protocol is already sufficient for purifying inhibitor-free and 
concentrated   DNA templates  when  compared  to a  direct elution  from  dried  
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Figure 3. Schematic composition of partial screening costs in a TREC-only and 
multiplexed TREC+KREC newborn screening assay. 
 
whole blood. Thus, particularly in the low-copy range, a better resolution can be 
achieved for the screening test (Figure 1). This is particularly relevant with 
regard to the determination of an appropriate diagnostic threshold (cut-off), as 
congenital T- or B-lymphopenias are not observed solely in patients with SCID 
or XLA (42). A TREC–KREC screening test that offers a good resolution for 
low copy numbers, allows for the implementation of a diagnostic threshold 
defined by the user in the screening lab, thus making it possible to differentiate 
"typical" SCID and XLA patients from those with borderline screening results 
observed in profound combined immunodeficiency diseases (Figure 4).  
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Figure 4. Relevance of the chosen cutoff values for TREC and KREC copy 
numbers on a population-scale screening basis with regard to expected SCID and 
PCID entities. 
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For a routine TREC–KREC screening, it is necessary to evaluate the test 
characteristics firstly in the local newborn population within a routine screening 
lab, and then to keep on validating them continuously. Usually, the copy 
numbers of TRECs and KRECs in the overall population are not normally 
distributed, so that 5,000 to 10,000 newborn samples should be evaluated in 
order to determine suitable diagnostic cut-offs in the low copy number range and 
to be able to estimate the repeat rate of the screening in this range. We have been 
performing such analyses using a TREC-KREC-ACTB screening assay as 
described in publications III, IV and V (Figures 5-1 and 5-2).  
 
 
Figure 5-1. Establishing population-acceptable diagnostic cutoff values for 
TREC and KREC copy numbers using the assay described in publications III, IV 
and V.  
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Figure 5-2. Outcome of two harmonized, prospective TREC-KREC-ACTB 
newborn screening studies in Stockholm and Leipzig; updated August 2014. 
 
Currently, most screening tests used in the U.S. and Europe have been developed 
in-house, which makes it difficult to harmonize the methodology and transfer 
diagnostic cut-offs (Figure 5-2). The dried blood cards provided by the Center 
for Disease Control and Prevention (CDC) for the purpose of collaborative trials 
have been validated only in terms of the T-cell numbers, which means they will 
yield incomplete results when used for TREC–KREC screening tests. Therefore, 
for the continuous validation of the TREC–KREC screening test, artificial 
control samples should be produced (1: T- B+, 2: T+ B-, 3: T- B-, 4: T+ B+); 
this can be achieved by the depletion of T- and/or B-lymphocytes, e.g. in 
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umbilical cord blood as donor material. Alternatively, EBV cell lines can also be 
used in this context that carry genomically stable copies of the TREC or KREC 
signal joint. When selecting an absolute quantification mode, it is preferable to 
document the measured copy numbers of these control samples prospectively to 
complete the required quality assurance at the screening laboratory. 
Depending on established diagnostic thresholds, prospective TREC–KREC 
screening results can be considered "normal" (equal to or above the thresholds 
for TRECs and KRECs) or "positive" (below the cut-offs for TRECs and/or 
KRECs) (Figures 5-1 and 5-2). In the event of a positive test result of the first 
dried blood spot punch, the lab runs an internal repeat test with two other 
punches from the same Guthrie card. The tracking process is initiated only if the 
two punches also yield positive test results. The proportion of newborns in the 
overall population for whom a separate, second Guthrie card has to be submitted 
is expressed as the tracking or re-call rate. The difference between repeat and 
tracking percentages is primarily due to pre-analytical factors, such as the 
method of producing the dried blood card and the selection of the punch position 
on the card. The selection of appropriate diagnostic thresholds should, however, 
also be based on these percentages to ensure that the screening test remains 
reasonable with respect to the overall population.  
 
4.3     Tracking process for severe PID 
     Tracking of newborns is usually initiated in case of repeatedly positive test 
results for TREC and/or KREC copy numbers after examination of at least three 
independent dried blood punches from the first Guthrie card submitted to the 
screening lab (Figures 5-1 and 5-2). The coordination and documentation of the 
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tracking in this case lies in direct responsibility of the screening laboratory that 
has performed the initial TREC–KREC screening test, but can also be passed to 
a specialized tracking center. 
Firstly, the obstetric unit (‘doctor–doctor’ interaction) and the parents of the 
newborn (‘doctor–patient’ interaction) should be contacted to obtain additional 
information on the status of the child. Since repeatedly positive TREC and/or 
KREC test results can occur especially in preterm infants (<32nd week of 
pregnancy), children with syndromic diseases (e.g., trisomy 21 or 22q11 
microdeletion), metabolic diseases (such as propionyl-CoA carboxylase 
deficiency or methylmalonic aciduria), and severe congenital infections or 
malformations with subsequent lymphocyte extravasation (e.g., neonatal sepsis 
or gastroschisis), it is important to gather and compile additional examination 
findings to evaluate a suspected diagnosis of a severe congenital 
immunodeficiency (publications IV and V, 42). If no TREC and/or KREC 
copies can be detected reliably at all in the three repeat samples of the first 
Guthrie card, one has to assume an "urgently positive" finding. In these rare 
cases, one should immediately counsel clinical consultation on the strong 
suspicion of SCID and/or XLA. Within the prospective study on anonymized 
DBS in 2012 (Figure 5-1), we have been identifying a neonate with <1/µl copies 
of KRECs, which later on proved to harbor a BTK gene mutation resulting in 
XLA (Figure 6) (43).   
In any other case, a separate second Guthrie card is immediately ordered to do a 
follow-up on the newborn. In the case of preterm infants, the second dried blood 
spot should probably not be sent in before the calculated date of delivery. If the 
second Guthrie card confirms the initial positive screening result, a persistent T- 
and/or B-lymphopenia should be assumed and an experienced pediatrician, 
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preferably associated with an immunodeficiency center, should be consulted. To 
this end, the screening laboratory will compile all additional available test 
results, especially those of the regular newborn screening that might suggest the 
existence of a metabolic disorder. 
 
 
Figure 6. Electropherogram of the disease causing XLA point mutation in Exon 
15 of the BTK gene (c.1480C>T, p.Q494X), leading to a premature stop codon in 
the TK domain. This mutation has been described before in XLA patients with 
an ethnic origin located in Serbia (43). 
 
4.4     Immunophenotype in premature newborns 
     Infants born before 37 weeks of gestation may suffer from a variety of 
cardiovascular, neurological, metabolic and gastrointestinal complications, in 
addition to an increased susceptibility to respiratory and urinary tract infections 
(42). Although many risk factors have been linked to preterm birth, the 
multifactorial causes remain unresolved in most of the affected infants, limiting 
the availability of effective interventions.  In developed countries, the birth rate 
of premature newborns is about 5 to 12 % with a tendency to rise, posing a 
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concern for newborn screening programs in particular and for public healthcare 
systems in general.  Thus, if dried blood spot samples are taken before the 32nd 
week of gestation, a second analysis later on for newborn screening tests of 
metabolic disorders to distinguish abnormal results of genetic origin from 
physiological immaturity often is required (42). 
A higher rate of abnormal test results for preterm infants has previously been 
observed in the TREC assay (44).  In this context, the immaturity of the immune 
system as a temporal effect of the gestational age may well be distinguished 
from specific factors related to the medical condition of preterm newborns. 
These factors are likely to include congenital anomalies, infectious 
complications and disturbed metabolic and endocrinologic conditions that may 
contribute to thymic stress and reduced output of recent thymic emigrants (45). 
Few data on reference ranges for TREC and KREC copy numbers has been 
published for premature infants, resulting in different practices for repeat testing 
of samples and referral of patients. In groups of premature newborns sorted by 
gestational age in weeks, analysis of TREC and KREC copy numbers tended to 
be consistent until 28 weeks age of gestation, though outliers with the detected 
frequencies would have an impact in regular newborn screening programs 
(Figure 7). Thus, samples from premature infants are basically eligible to be 
analyzed by excision circle assays, and might also not have to be retested at a 
later stage if cut-off values to have been exceeded initially. 
 
4.5     Follow-up diagnostics 
     The follow-up diagnostics of newborns suspected of a severe PID have to 
meet several requirements at the same time. On the one hand, the repeatedly 
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positive screening result has to be confirmed by way of exploratory (complete 
blood count) and detailed cytological tests (flow cytometry). On the  other  hand,  
 
 
Figure 7. TREC and KREC copy numbers in neonatal DBS of premature born 
infants. Cutoff values: TREC <8 copies, KREC <4 copies. 
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conclusions should be drawn from immunofunctional and molecular genetic tests 
about the pathogenetic background of each patient in preparation of an 
individualized treatment plan. The need for such patient-centered follow-up 
diagnostics is derived from the considerable molecular heterogeneity of severe 
PID with numerous "private" mutations. 
Flow cytometric lymphocyte typing is to provide a confirmation of the screening 
suspicion by means of a methodologically independent, peripheral whole blood 
examination and at the same time describes the composition of lymphocyte 
subpopulations, including recent thymic emigrants (RTE), and excludes a 
maternal engraftment with CD45RO+ T-cells. While in patients with "typical" 
SCID phenotypes or agammaglobulinemia, the almost complete absence of 
autologous T- and/or B-lymphocytes (< 300 T-cells and/or < 100 B-cells per 
microliter of whole blood) already is a clear diagnostic signal, reduced T-cell 
numbers (300–1500 T-cells per microliter of whole blood) may be detectable in 
clinically relevant PCID phenotypes (Figure 4). However, normal T-cell 
numbers can also be observed simultaneously with reduced B-cell numbers in 
newborns with "delayed-onset" ADA SCID, indicating that a SCID phenotype 
has always to be considered in connection with an isolated decrease in KREC 
copy numbers (46). 
Immunophenotyping often fails to provide a definitive assessment of the 
functional relevance of an anticipated severe PID, especially when the flow 
cytometric analysis or clinical examination suggests the existence of an 
"atypical" phenotype. Therefore, for the completion of flow cytometric tests, (i) 
the lymphocytic proliferation and stimulation ability, as well as (ii) the 
functionality of the innate diversity of the immune repertoire should also be 
examined in-vitro. 
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4.6     Confirmatory genetic testing 
     Currently, more than 18 monogenetic defects have been described, resulting 
in a phenotype of severe combined immunodeficiencies [47]. Likewise, primary 
agammaglobulinemia with some missing B-lymphocytes can be traced back to 
more than six genetic defects (1). In terms of pathogenesis, the underlying 
defects can be associated with maturation disorders, especially of the lymphatic 
lineage in the bone marrow, as well as in primary and secondary lymphatic 
tissues. Flow cytometric evaluation of the peripheral blood makes it possible for 
SCID patients to be classified according to the T- B+/- NK+/- system, which can 
further indicate the underlying genetic defect (1). The molecular and cellular 
functional heterogeneity of severe combined immunodeficiencies is also evident 
in the clinical treatment experience, which led to the application of "gene-
specific" protocols in conditioning and stem cell transplantation or gene therapy 
for SCID patients (48,49).  
While the decision for stem cell transplantation has so far been based on the 
clinical course, as well as cellular and immunofunctional tests, the pre-
symptomatic early identification of newborns with severe PID poses a new 
challenge for the algorithms of treatment decision. Immunological function 
testing of infants, in particular, is struggled by the lack of sufficient reference 
ranges, because age-weighted control samples are not regularly available. 
Therefore, molecular genetic tests are of special importance for newborns with 
neonatal deficiency of autologous T-lymphocytes and a suspected SCID or PCID 
phenotype. At the same time, the initiation of a curative therapy should not be 
delayed, neither by the time required for molecular testing, nor by the absence of 
a final genetic diagnosis. In newborns with severe neonatal deficiency of 
autologous B-lymphocytes and suspicion of agammaglobulinemia, the 
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transferred maternal immunity, which usually lasts up to 6 months following 
birth, can help to sustain the time until a complete genetic diagnosis prior to the 
start of treatment is made (50). 
Currently, molecular genetic testing in a clinical context is predominantly 
performed through selection of annotated candidate genes for the suspected 
congenital immunodeficiency. However, the limitation to candidate genes 
represents a problem with regard to the molecular heterogeneity and the known 
overlapping effects in the clinical phenotype, especially in the case of a 
sequential approach ("gene-by-gene"). More recent molecular genetic methods 
can partially or completely avoid these disadvantages, but sequence-analytical 
challenges in view of ever increasing amounts of data currently represent the 
primary obstacle to a timely reporting of results. On the one hand, specific exon 
enrichment (e.g. HaloPlex system) makes it possible to accommodate 
individualized diagnostic panels for up to 250 candidate genes on a single 
microfluidic gene chip. On the other hand, the third generation of sequencers 
holds out the promise of a cost- and time-efficient analysis of entire 
transcriptomes, exomes or even genomes (51). The advantage of transcriptome- 
or exome-wide tests is the ability to simultaneously examine comprehensively 
known candidate genes sequentially and to identify new disease-associated genes 
for PID. In view of the evidence-based justification for lifelong supportive or 
invasive therapies, such as a hematopoietic stem cell transplantation, this will 
become increasingly important (52). 
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CONCLUSIONS AND FUTURE PERSPECTIVES 
 
The aim of this thesis was to present newly developed diagnostic assays to be 
used for newborn screening of severe primary immunodeficiencies, including 
SCID, XLA and FHL3 due to an UNC13D inversion. The conclusions drawn 
from the individual publications in the thesis are: 
 
1.  A triplex real-time quantitative PCR assay for measurement of 
TREC, KREC and ACTB copy numbers in dried blood spot specimen is a 
suitable tool for identification of PID characterized by a severe T and/or B 
cell lymphopenia at birth, without disclosing functional B cell 
immunodeficiencies with normal absolute B cell counts (Publication I). 
 
2.  Analysis of IgA-protein levels in Guthrie card samples is not 
effective as a screening tool for PID due to maternal transfer of IgA. Other 
protein based screening assays, however, might be beneficial in NBS for 
severe PID (Publication II). 
 
3.  Combination of the TREC-KREC screening assay with 
measurement of the UNC13Dwt allele in exchange for ACTB allows 
identifying patients with FHL3 due to an UNC13D inversion. This indicates 
that the TREC-assay can be multiplexed with two more relevant 
biomarkers for early identification of severe PID (Publication III). 
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4.     An improved version of the TREC-KREC-ACTB screening 
assay, developed in Publication I, allows for reduction of TREC and KREC 
cutoff levels without reducing the sensitivity to identify newborns with 
SCID and XLA. Neonates with Down syndrome present only a small 
fraction of positive screening results and exclusion is possible based on a 
qPCR second-tier assay (Publication IV). 
 
5. Retrospective analysis of Guthrie card samples from DiGeorge 
patients using the TREC-KREC screening assay identifies a high 
proportion of neonates with T cell lymphopenia and subsequently increased 
viral infections in early life. The development of a second-tier qPCR assay 
allows identifying newborns with 22q11 microdeletions in dried blood spots 
(Publication V). 
 
The use of excision circle assays has not proven to be helpful for early detection 
of antibody deficiencies such as common variable immunodeficiency (CVID), 
Hyper-IgM syndromes (HIGM) or selective IgA deficiency (IgAD), nor would 
these assays be expected to identify patients with complement deficiencies. (42) 
Moreover, disorders that are detected only partially by TREC / KREC assays 
will require alternative screening approaches to be eligible for preventive 
programs.  
To overcome the difficulties to find common delineators for PID screening, it 
might be useful in the future to develop assays that measure disease-specific 
biomarkers. A variety of potential biomarkers for PID have been proposed 
before (42), and suitable technological platforms and nanomaterials for 
  47 
immunoassays and enzyme activity assays have been developed in recent years. 
Our group has previously demonstrated that analyzing a multitude of serum 
protein levels is also feasible using reverse phase protein microarrays, a 
technique that can be adapted for the screening of C3 complement deficiency in 
eluted dried blood spot cards and might also be expanded on low abundance 
complement factor deficiencies. Combining this protein microarray platform 
with digital microfluidics in the future has furthermore the potential to markedly 
reduce the amount of reagents and time consumed.   
One of the technologies that could be employed in future newborn screening is 
based on proximity ligation of unique nucleic acid flags, which can be attached 
to diagnostic antibodies or designed to capture bacterial or viral recognition 
sequences directly (42).  The proximity ligation assay (PLA) offers a possibility 
for multiplex analysis and quantitation of proteins in nanoliter volumes of crude 
sample mixtures with a sensitivity reaching the picomolar range. 
Our future focus will be directed towards functional PID to be included in 
newborn screening assays, particularly defects of phagocytic function and PCID 
currently not detected in excision circle assays. The economical evaluation of the 
cost-effectiveness of novel technologies for neonatal screening is a challenging 
mission, as various factors – that may also underlie regional or country-specific 
characteristics – determine the outcome of such analyses (42). 
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